跳转至内容
Merck
CN

407602

Interleukin-1 Receptor-Associated-Kinase-1/4 Inhibitor

InSolution, ≥98%

别名:

InSolution Interleukin-1 Receptor-Associated-Kinase-1/4 Inhibitor, N-(1-(2-morpholinoethyl)-1H-benzo[d]imidazol-2-yl)-3-nitrobenzamide, N-(2-Morpholinylethyl)-2-(3-nitrobenzoylamido)-benzimidazole

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C20H21N5O4
化学文摘社编号:
509093-47-4
分子量:
395.41
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD09752602

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Interleukin-1 Receptor-Associated-Kinase-1/4 Inhibitor, InSolution, ≥98%

SMILES string

[N+](=O)([O-])c1cc(ccc1)C(=O)Nc2[n](c4c(n2)cccc4)CCN3CCOCC3

InChI

1S/C20H21N5O4/c26-19(15-4-3-5-16(14-15)25(27)28)22-20-21-17-6-1-2-7-18(17)24(20)9-8-23-10-12-29-13-11-23/h1-7,14H,8-13H2,(H,21,22,26)

InChI key

QTCFYQHZJIIHBS-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

liquid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
avoid repeated freeze/thaw cycles
desiccated (hygroscopic)
protect from light

shipped in

dry ice

storage temp.

−70°C

Quality Level

100

相关类别

Biochem/physiol Actions

Reversible: yes
Target IC50: 300 nM and 200 nM for IRAK-1 and -4
Primary Target
IRAK-1/4

Disclaimer

Toxicity: Irritant (B)

General description

A cell-permeable benzimidazole compound that acts as a potent and selective inhibitor of interleukin-1 receptor-associated kinases (IC50 = 300 nM and 200 nM for IRAK-1 and -4). Shown to exhibit little activity against a panel of 27 other kinases (IC50 >10 µM), including lck and src. The solid form of this compound (Cat. No. 407601) is also available.

Other Notes

Srivastava, R., et al. 2012. Cancer Res.72, In press.
Bhattacharyya, S., et al. 2007. Am. J. Physiol. Gastrointest. Liver Physiol.293, G429.
Powers, J.P., et al. 2006. Bioorg. Med. Chem. Lett.16, 2842.

Packaging

Packaged under inert gas

Preparation Note

Following initial thaw, aliquot and freeze (-70°C). Aliquots are stable for up to 6 months at -70°C.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

存储类别

10 - Combustible liquids

wgk

WGK 2

flash_point_f

188.6 °F - closed cup - (refers to pure substance)

flash_point_c

87 °C - closed cup - (refers to pure substance)

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Ratika Srivastava et al.
Cancer research, 72(23), 6209-6216 (2012-10-09)
Toll-like receptors (TLR) are expressed by a variety of cancers, including melanoma, but their functional contributions in cancer cells are uncertain. To approach this question, we evaluated the effects of stimulating or inhibiting the TLR/IL-1 receptor-associated kinases IRAK-1 and IRAK-4
Humayara Khan et al.
3 Biotech, 13(1), 14-14 (2022-12-22)
Combination of docetaxel, cisplatin and 5-FU, known as TPF, is an FDA-approved treatment for head and neck squamous cell carcinoma (HNSCC). Acquired chemo-resistance to TPF, a primary reason for non-responsiveness to the treatment and relapse of tumor is a major
Jay P Powers et al.
Bioorganic & medicinal chemistry letters, 16(11), 2842-2845 (2006-03-28)
High-throughput screening of a small-molecule compound library resulted in the identification of a novel series of N-acyl 2-aminobenzimidazoles that are potent inhibitors of interleukin-1 receptor-associated kinase-4.
Sumit Bhattacharyya et al.
American journal of physiology. Gastrointestinal and liver physiology, 293(2), G429-G437 (2007-06-02)
Lipopolysaccharide (LPS) is recognized as an inducer of the inflammatory response associated with gram-negative sepsis and systemic inflammatory response syndrome. LPS induction proceeds through Toll-like receptor (TLR) in immune cells and intestinal epithelial cells (IEC). This report presents the first

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持